Some US Food and Drug Administration officials may be willing to consider artificial intelligence models that are not fully explainable, but Chief Medical Officer Hilary Marston seems concerned about their use in applications, further illustrating the agency’s ongoing challenge regulating the emerging technology.
Key Takeaways
- FDA CMO Hilary Marston said an AI black box could be problematic because reviewers like to redo analyses in applications.
AI models sometimes produce the expected output, but their creators cannot fully explain how the model reached the answer or...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?